HRS-2189 + HRS-8080

HRS-2189 + HRS-8080 is a combination investigational therapy being evaluated for advanced, unresectable, or metastatic breast cancer. Both are oral, small molecule drugs under clinical development, often studied together in multi-arm, early-phase clinical trials. As of September 2025, both agents are the subject of Phase 1/2 studies, primarily sponsored by Shandong Suncadia Medicine, to evaluate their safety, tolerability, pharmacokinetics, and preliminary efficacy, including regimens where HRS-2189 is given in combination with HRS-8080, with or without other investigational agents. Both drugs appear to be novel molecules, and Hengrui Medicine is cited as a principal developer for both. The precise mechanism of action of each component has not been publicly disclosed, but available sources indicate they may be part of ongoing efforts in targeted or small-molecule oncology therapeutics, potentially as protein degraders or targeted pathway inhibitors.